ReviewRadiolabelled proteins for positron emission tomography: Pros and cons of labelling methods
Section snippets
Applications of polypeptides as imaging probes
Interest in the use of radiolabelled proteins and peptides both as imaging tools during preclinical development and as clinical diagnostics and therapeutics has been increasing during the last decade. This is to a large extent due to the success of genomics and proteomics in identifying disease-related aberrations in the structure or expression levels of cellular proteins. This basic knowledge is rapidly being translated into the development of specific therapeutics that act by the molecular
Positron emission tomography as the imaging technique
PET is an in vivo tomographic imaging technique. It is based on the detection of anti-parallel 511 keV photons emitted during the annihilation of positrons with electrons. The positrons come from the decay of positron-emitting nuclides. If those radionuclides are appropriately attached to a molecule of interest, PET measurements of the concentrations of radioactivity throughout a body can be used to make deductions about the molecule's distribution, metabolism, elimination, ability to interact
Some general considerations on the selection of a label
Depending on the intended application of the labelled biomolecule, the requirements made on the radiolabelling method will differ substantially:
For pharmacokinetics studies, it is essential that the distribution of the radioactivity should reflect as accurately as possible that of the non-labelled molecule. Therefore the label and linker should generally be small and should not appreciably affect the biomolecule's lipophilicity, folding, biological activity, etc. The tracing ability of the
Influence of the labelling method on the biodistribution and targeting properties of a tracer
It is important to remember that neither PET nor any of the nuclide-based in vivo imaging techniques track a molecule's localization in a target or even the biodistribution of a labelled molecule. PET visualizes (and provides quantitative information about) the distribution of a radioactivity concentration in vivo. The radioactivity may be the tracer bound to its target, the non-bound tracer, radiometabolites or a combination of these. If the goal of the experiment is to visualize and quantify
Experiences in labelling proteins with positron-emitting radionuclides
The development and clinical use of PET have mainly been based on the use of short-lived (half-lives of 2–110 min) nuclides 15O, 13N, 11C and 18F. The majority of strategies for radiolabelling proteins for PET have been performed with the more long-lived nuclides, primarily because it has been more appropriate for probes expected to stay in circulation for long times and, practically, because it is much easier to not have to work so “on-line” with a cyclotron facility by using the oxidative
Acknowledgements
Vladimir Tolmachev expresses his gratitude to the Swedish Medical Research Council (Vetenskapsrådet) for supporting his research in medical imaging and Sharon Stone-Elander gratefully acknowledges funding for radiolabelling protein probes for PET from the Swedish Medical Research Council (K2009-53X-20033-04-2) and Swedish Agency for Innovation Systems (Vinnova; 2009-00179).
References (347)
- et al.
Three-dimensional imaging-based radiobiological dosimetry
Semin. Nucl. Med.
(2008) - et al.
Scaffolds for engineering novel binding sites in proteins
Curr. Opin. Struct. Biol.
(1997) - et al.
Artificial, non-antibody binding proteins for pharmaceutical and industrial applications
Trends Biotechnol.
(2005) Alternative non-antibody scaffolds for molecular recognition
Curr. Opin. Biotechnol.
(2007)- et al.
Selection and characterization of Her2 binding-designed ankyrin repeat proteins
J. Biol. Chem.
(2006) - et al.
A designed ankyrin repeat protein evolved to picomolar affinity to Her2
J. Mol. Biol.
(2007) - et al.
A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin
Nucl. Med. Biol.
(2002) Molecular engineering and design of therapeutic antibodies
Curr. Opin. Immunol.
(2008)Radioimmunodetection and therapy of breast cancer
Semin. Nucl. Med.
(2005)- et al.
Biodistribution of 111In-DTPA-D-Phe1-octreotide in tumour-bearing nude mice: influence of amount injected and route of administration
Nucl. Med. Biol.
(2003)
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)
Nucl. Med. Biol.
A novel bifunctional maleimido CHX-A″ chelator for conjugation to thiol-containing biomolecules
Bioorg. Med. Chem. Lett.
Label stability in serum of four radionuclides on DTPA-coupled antibodies—an evaluation
Int. J. Radiat. Appl. Instrum., B
Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity
Mol. Immunol.
Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling
Nucl. Med. Biol.
Immuno-PET: a navigator in monoclonal antibody development and applications
Oncologist
Novel antibodies as anticancer agents
Oncogene
Radionuclide therapy of cancer with radiolabeled antibodies
Anticancer Agents Med. Chem.
Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab
Oncogene
Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation
Clin. Cancer. Res.
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice
J. Nucl. Med.
Targeting peptides and positron emission tomography
Biopolymers
Development and application of peptide-based radiopharmaceuticals
Anticancer Agents Med. Chem.
Peptide-based probes for cancer imaging
J. Nucl. Med.
Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases
Curr. Pharm. Des.
Candidates for peptide receptor radiotherapy today and in the future
J. Nucl. Med.
Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy
Cancer Biother. Radiopharm.
Optimizing the affinity and specificity of proteins with molecular display
Mol. Biosyst.
In vitro display technologies reveal novel biopharmaceutics
FASEB J.
Engineering novel binding proteins from nonimmunoglobulin domains
Nat. Biotechnol.
Affibody molecules for molecular imaging and therapy of cancer
Cancer Biother. Radiopharm.
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy
Curr. Opin. Drug Discov. Dev.
PET versus SPECT: strengths, limitations and challenges
Nucl. Med. Commun.
Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice
Cancer Res.
Positron emission tomography and radioimmunotargeting. General aspects
Acta Oncol.
Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Eur. J. Nucl. Med.
Positron emission tomography and radioimmunotargeting. Aspects of quantification and dosimetry
Acta Oncol.
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
Eur. J. Nucl. Med. Mol. Imaging
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy
Eur. J. Nucl. Med. Mol. Imaging
In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors
Clin. Cancer Res.
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implication for in vivo dosimetry
Cancer Biother. Radiopharm.
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies
J. Nucl. Med.
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET
Cancer Biother. Radiopharm.
89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab
J. Nucl. Med.
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
Eur. J. Nucl. Med. Mol. Imaging
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
Eur. J. Nucl. Med. Mol. Imaging
Engineering therapeutic monoclonal antibodies
Immunol. Rev.
New developments in monoclonal antibodies for cancer detection and therapy
CA Cancer. J. Clin.
Pharmacokinetics and biodistribution of genetically-engineered antibodies
Q. J. Nucl. Med.
Tailoring antibodies for radionuclide delivery
Expert Opin. Drug Deliv.
Cited by (81)
Radiolabeled Peptides and Antibodies in Medicine
2021, Bioconjugate ChemistryPositron emission tomography as a noninvasive tool in pharmacokinetic studies
2021, Biopharmaceutics and Pharmacokinetics Considerations: Volume 1 in Advances in Pharmaceutical Product Development and ResearchNew excitation functions measurement of nuclear reactions induced by deuteron beams on yttrium with particular reference to the production of <sup>89</sup>Zr
2019, Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and AtomsClinical Applications of Radiolabeled Peptides for PET
2017, Seminars in Nuclear Medicine